Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Chemotherapy-Related Cognitive Dysfunction in Breast Cancer
- Vandetanib in Locally Advanced or Metastatic Differentiated Thyroid Cancer
- Taxane-Induced Neuropathy and Outcome in Operable Breast Cancer
- Four Cycles of Adjuvant Therapy for Low-Risk Breast Cancer
- Dabrafenib in BRAF-Mutated Metastatic Melanoma
- T-DM1 Active in Highly Refractory HER2-Positive Breast Cancer
- Encouraging Results With MRI in BRCA-Mutated Breast Cancer
- US Task Force Confirms Stance Against Universal PSA Screening
- Everolimus Plus Tamoxifen Improves Survival in Metastatic Breast Cancer
- DCIS: A Long-Term Risk Factor for Breast Cancer